EDX Medical service agreement with Astron Health

EDX Medical Group PLC

08 July 2026

 

08 July 2026

EDX Medical Group plc · EDX

("EDX Medical" or the "Company")

EDX MEDICAL PROVIDES MOLECULAR PROFILING SERVICE TO ASTRON HEALTH

CAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer and infectious diseases, announces that the Company has been appointed to provide molecular profiling products and services to Astron Health Ltd ("Astron"), a global oncology service providing precision oncology second opinions and molecular profiling interpretation.

Under the agreement with Astron, EDX Medical will provide in the UK a service and highly accurate diagnostic tests that include Caris MI Profile™, a comprehensive tumour profiling platform designed to guide precision oncology, and Caris Assure^®, blood based comprehensive molecular profiling designed for patients with previously diagnosed solid tumours and where tissue biopsy is not feasible.

Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: "We are delighted that Astron, which operates globally, has chosen EDX Medical as the right partner in the UK to supply the most advanced and detailed cancer tests which are renowned for equipping oncologists and doctors with highly accurate molecular information to guide treatment decisions. We see this type of partnership as validation of our strategy to provide the world's best diagnostic tests that shape the treatment of major diseases and help save lives."

Dr Padman Vamadevan, co-founder and chief medical officer of Astron Health, commented: "As a company that provides precision oncology second opinions and molecular profiling interpretation for patients and doctors worldwide, it is essential that we have access to the best-in-class diagnostic tests that will inform clinicians and their patients. We are very pleased to have EDX Medical supplying a molecular profiling service in the UK."

Astron interprets molecular tumour profiling to help clinicians understand what is driving a patient's cancer. The company's molecular tumour board translate these findings into evidence-graded second opinions and management options for the primary clinical teams to consider.

For enquiries, please contact:

EDX Medical Group plc
Dr Mike Hudson (Chief Executive Officer)	[phone]
Canaccord Genuity Limited (Nominated Adviser and Broker)
Stuart Andrews	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] + 44 (0)7834 694609 [e-mail]
IFC Advisory (Investor Relations)
Graham Herring Tim Metcalfe	[phone]

About EDX Medical Group plc

The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

 

END